Compare · NVS vs SIGA
NVS vs SIGA
Side-by-side comparison of Novartis AG (NVS) and SIGA Technologies Inc. (SIGA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and SIGA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $292.08B, about 942.7x SIGA ($309.8M).
- Over the past year, NVS is up 29.5% and SIGA is down 33.6% - NVS leads by 63.1 points.
- SIGA has been more active in the news (8 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 0 for SIGA).
- Company
- Novartis AG
- SIGA Technologies Inc.
- Price
- $152.93-0.66%
- $4.32+0.35%
- Market cap
- $292.08B
- $309.8M
- 1M return
- +2.10%
- +0.23%
- 1Y return
- +29.48%
- -33.59%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 1
- 8
- Recent ratings
- 25
- 0
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
SIGA Technologies Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was founded in 1995 and is headquartered in New York, New York.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
Latest SIGA
- Director Marshall Joseph W Iii converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 7% to 246,523 units (SEC Form 4) (withholding tax)
- Director Keane John M converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39) (SEC Form 4) to satisfy withholding obligation
- Director Ford Harold Eugene Jr. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 55% to 47,538 units (SEC Form 4) (withholding obligation)
- Director Phillips Holly L. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 30% to 73,754 units (SEC Form 4) to cover withholding tax
- Director Nemirovsky Julian converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 30% to 73,754 units (SEC Form 4) to satisfy withholding obligation
- Director Durnan Jaymie A converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 23% to 88,754 units (SEC Form 4) (tax liability)
- Director Nabel Gary J. converted options into 24,116 shares and returned $31,762 worth of shares to the company (7,235 units at $4.39), increasing direct ownership by 30% to 73,754 units (SEC Form 4) (for tax liability)
- SIGA Technologies Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by SIGA Technologies Inc.
- SEC Form 10-Q filed by SIGA Technologies Inc.